The burden of bladder cancer care: direct and indirect costs

被引:143
作者
Mossanen, Matthew [1 ]
Gore, John L. [1 ]
机构
[1] Univ Washington, Sch Med, Washington Sch Med, Dept Urol, Seattle, WA 98195 USA
关键词
bladder cancer; cost; quality of care; quality of life; QUALITY-OF-LIFE; INVASIVE UROTHELIAL CARCINOMA; FOLLOW-UP; TRANSURETHRAL RESECTION; FLUORESCENCE CYSTOSCOPY; RADICAL CYSTECTOMY; URINARY-BLADDER; STAGE-TA; IN-SITU; RECURRENCE;
D O I
10.1097/MOU.0000000000000078
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Bladder cancer is a common, complex, and costly disease. Every year in the USA, bladder cancer is responsible for 70 000 diagnosed cases and over 15 000 deaths. Once diagnosed, patients with nonmuscle invasive bladder cancer (NMIBC) are committed to a lifetime of invasive procedures and potential hospitalizations that result in substantial direct and indirect costs. Recent findings Bladder cancer is the most costly cancer among the elderly, estimated at nearly $4 billion per year, and has the highest cost of any cancer when categorized on a per patient basis. The direct economic cost of NMIBC is fueled by the need for lifelong cystoscopic examination and variations in treatment algorithms. This fiscal burden is further compounded by the indirect impact on psychological health and quality of life of patients and their families. Despite the development of new technologies, such as novel urinary biomarkers and innovative cystoscopic methods, no alternative to cystoscopic surveillance has been established. Summary The management of patients with NMIBC is responsible for a substantial financial burden with indirect costs that extend beyond quantifiable direct costs.
引用
收藏
页码:487 / 491
页数:5
相关论文
共 51 条
[1]   Quality of life in long-term survivors of bladder cancer. [J].
Allareddy, Veerasathpurush ;
Kennedy, Julianna ;
West, Michele M. ;
Konety, Badrinath R. .
CANCER, 2006, 106 (11) :2355-2362
[2]  
Anastasiadis A, 2012, EXPERT REV ANTICANC, V12, P1229, DOI [10.1586/ERA.12.98, 10.1586/era.12.98]
[3]   Best practice in the treatment of nonmuscle invasive bladder cancer [J].
Anastasiadis, Anastasios ;
de Reijke, Theo M. .
THERAPEUTIC ADVANCES IN UROLOGY, 2012, 4 (01) :13-32
[4]  
[Anonymous], Cancer Facts & Figures
[5]   Clinical model of lifetime cost of treating bladder cancer and associated complications [J].
Avritscher, Elenir B. C. ;
Cooksley, Catherine D. ;
Grossman, H. Barton ;
Sabichi, Anita L. ;
Hamblin, Lois ;
Dinney, Colin P. ;
Elting, Linda S. .
UROLOGY, 2006, 68 (03) :549-553
[6]   EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013 [J].
Babjuk, Marko ;
Burger, Maximilian ;
Zigeuner, Richard ;
Shariat, Shahrokh F. ;
van Rhijn, Bas W. G. ;
Comperat, Eva ;
Sylvester, Richard J. ;
Kaasinen, Eero ;
Boehle, Andreas ;
Palou Redorta, Joan ;
Roupret, Morgan .
EUROPEAN UROLOGY, 2013, 64 (04) :639-653
[7]   The health economics of bladder cancer - A comprehensive review of the published literature [J].
Botteman, MF ;
Pashos, CL ;
Redaelli, A ;
Laskin, B ;
Hauser, R .
PHARMACOECONOMICS, 2003, 21 (18) :1315-1330
[8]   ICUD-EAU International Consultation on Bladder Cancer 2012: Non-Muscle-Invasive Urothelial Carcinoma of the Bladder [J].
Burger, Maximilian ;
Oosterlinck, Willem ;
Konety, Badrinath ;
Chang, Sam ;
Gudjonsson, Sigurdur ;
Pruthi, Raj ;
Soloway, Mark ;
Solsona, Eduardo ;
Sved, Paul ;
Babjuk, Marko ;
Brausi, Maurizio A. ;
Cheng, Christopher ;
Comperat, Eva ;
Dinney, Colin ;
Otto, Wolfgang ;
Shah, Jay ;
Thuerof, Joachim ;
Witjes, J. Alfred .
EUROPEAN UROLOGY, 2013, 63 (01) :36-44
[9]   Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate [J].
Cauberg, Evelyne C. C. ;
Mamoulakis, Charalampos ;
de la Rosette, Jean J. M. C. H. ;
de Reijke, Theo M. .
WORLD JOURNAL OF UROLOGY, 2011, 29 (04) :503-509
[10]  
Cella D., 1997, MANUAL FUNCTIONAL AS